1. Home
  2. BMEA vs DSY Comparison

BMEA vs DSY Comparison

Compare BMEA & DSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMEA
  • DSY
  • Stock Information
  • Founded
  • BMEA 2017
  • DSY 2020
  • Country
  • BMEA United States
  • DSY China
  • Employees
  • BMEA N/A
  • DSY N/A
  • Industry
  • BMEA Biotechnology: Pharmaceutical Preparations
  • DSY
  • Sector
  • BMEA Health Care
  • DSY
  • Exchange
  • BMEA Nasdaq
  • DSY Nasdaq
  • Market Cap
  • BMEA 65.8M
  • DSY 58.8M
  • IPO Year
  • BMEA 2021
  • DSY N/A
  • Fundamental
  • Price
  • BMEA $1.73
  • DSY $1.57
  • Analyst Decision
  • BMEA Strong Buy
  • DSY
  • Analyst Count
  • BMEA 11
  • DSY 0
  • Target Price
  • BMEA $27.60
  • DSY N/A
  • AVG Volume (30 Days)
  • BMEA 713.5K
  • DSY 63.8K
  • Earning Date
  • BMEA 05-05-2025
  • DSY 02-10-2025
  • Dividend Yield
  • BMEA N/A
  • DSY N/A
  • EPS Growth
  • BMEA N/A
  • DSY 120.37
  • EPS
  • BMEA N/A
  • DSY 0.01
  • Revenue
  • BMEA N/A
  • DSY $7,323,356.00
  • Revenue This Year
  • BMEA N/A
  • DSY N/A
  • Revenue Next Year
  • BMEA N/A
  • DSY N/A
  • P/E Ratio
  • BMEA N/A
  • DSY $124.18
  • Revenue Growth
  • BMEA N/A
  • DSY 16.37
  • 52 Week Low
  • BMEA $1.53
  • DSY $0.75
  • 52 Week High
  • BMEA $13.43
  • DSY $10.75
  • Technical
  • Relative Strength Index (RSI)
  • BMEA 41.85
  • DSY 57.19
  • Support Level
  • BMEA $1.61
  • DSY $1.12
  • Resistance Level
  • BMEA $2.30
  • DSY $1.57
  • Average True Range (ATR)
  • BMEA 0.20
  • DSY 0.18
  • MACD
  • BMEA -0.00
  • DSY 0.02
  • Stochastic Oscillator
  • BMEA 21.74
  • DSY 98.11

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

About DSY Big Tree Cloud Holdings Limited Ordinary Shares

Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.

Share on Social Networks: